Skip to main content
Terug
ALKS logo

Alkermes plc

Datakwaliteit: 100%
ALKS
NASDAQ Healthcare Biotechnology
€ 27,71
▼ € 0,44 (-1,56%)
Marktkapitalisatie: 4,62B
Dagbereik
€ 27,67 € 28,68
52-Weeksbereik
€ 25,17 € 36,32
Volume
2.131.543
50D / 200D Gem.
€ 31,35 / € 29,72
Vorige Slotkoers
€ 28,15

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 19,1 0,4
P/B 2,5 2,9
ROE % 14,7 3,8
Net Margin % 16,4 3,9
Rev Growth 5Y % 5,9 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 46,83 +69.0%
Low: € 43,00 High: € 56,00
Forward WPA
-€ 0,31
Omzet Sch.
1,8 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 3,17
€ 3,06 – € 3,39
2,5 B 4
FY2029 € 2,18
€ 2,10 – € 2,33
2,3 B 4
FY2028 € 1,45
-€ 0,26 – € 3,89
2 B 10

Belangrijkste Punten

Revenue grew 5,89% annually over 5 years — modest growth
Earnings declined -34,16% over the past year
ROE of 14,72% — decent returns on equity
Net margin of 16,37% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Generating 480,33M in free cash flow

Groei

Revenue Growth (5Y)
5,89%
Revenue (1Y)-5,25%
Earnings (1Y)-34,16%
FCF Growth (3Y)16,60%

Kwaliteit

Return on Equity
14,72%
ROIC10,08%
Net Margin16,37%
Op. Margin17,21%

Veiligheid

Debt / Equity
0,04
Current Ratio3,55
Interest Coverage20,69

Waardering

P/E Ratio
19,11
P/B Ratio2,54
EV/EBITDA14,05
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -5,25% Revenue Growth (3Y) -5,80%
Earnings Growth (1Y) -34,16% Earnings Growth (3Y) -17,58%
Revenue Growth (5Y) 5,89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,48B Net Income (TTM) 241,66M
ROE 14,72% ROA 9,55%
Gross Margin 86,31% Operating Margin 17,21%
Net Margin 16,37% Free Cash Flow (TTM) 480,33M
ROIC 10,08% FCF Growth (3Y) 16,60%
Safety
Debt / Equity 0,04 Current Ratio 3,55
Interest Coverage 20,69 Dividend Yield 0,00%
Valuation
P/E Ratio 19,11 P/B Ratio 2,54
P/S Ratio 3,13 PEG Ratio -0,56
EV/EBITDA 14,05 Dividend Yield 0,00%
Market Cap 4,62B Enterprise Value 3,57B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,48B 1,56B 1,66B 1,11B 1,17B
Net Income 241,66M 367,07M 355,76M -158,27M -48,17M
EPS (Diluted) 1,43 2,17 2,10 -0,97 -0,30
Gross Profit 1,27B 1,31B 1,41B 893,73M 976,43M
Operating Income 253,96M 420,64M 414,12M -6,09M 97,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,53B 2,06B 2,14B 1,96B 2,02B
Total Liabilities 710,96M 590,59M 933,54M 920,23M 911,90M
Shareholders' Equity 1,82B 1,46B 1,20B 1,04B 1,11B
Total Debt 70,00M 75,54M 372,19M 379,44M 416,21M
Cash & Equivalents 1,12B 291,15M 457,47M 292,47M 337,54M
Current Assets 1,93B 1,42B 1,49B 1,13B 1,06B
Current Liabilities 543,44M 465,20M 520,22M 497,74M 471,29M